Sign in
Taking people in HungaryPhase 4

Checks heart and blood vessel side effects of cancer immunotherapy drugs

Studies heart and blood vessel side effects in adults receiving immune checkpoint inhibitor cancer treatment.

Key facts

Who runs it
Semmelweis University
Where
Budapest VIII, HungarySee the site
Registry title
BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
Status
Recruiting
Phase
Phase 4
People taking part
1,000 people, planned
Started
20 Jan 2026
Expected to end
1 Jan 2031
Type of study
Interventional
Record updated
14 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer who are planning to start immune checkpoint inhibitor therapy. It studies the side effects on the heart and blood vessels.

Age
At least 18 years old.
Sex
All sexes can join.
Earlier treatment
Immune checkpoint inhibitor therapy must be planned.

Main reasons for not taking part

  • No signed informed consent
  • Under 18 years of age
  • Cannot read or write (illiteracy)
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients presented to the oncology teams of Semmelweis University and clinics in the country wishing to join the research
  • Planned immune checkpoint inhibitor therapy
  • At least 18 years of age
  • Signing of the patient information sheet and consent form by the patient
  • Accessible medical history

Who cannot take part

  • Age under 18
  • Lack of informed consent form
  • Illiteracy
  • Pregnancy and breastfeeding

Where in Hungary

  • Semmelweis UniversityBudapest VIII, HungaryTaking people

About the trial

What the trial wants to find out

In this study, we aim to investigate the cardiovascular side effects of immune checkpoint inhibitors.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
BudapestICIVasc: Cardiovascular side effects of immune checkpoint inhibitor oncological therapies and their monitoring in the context of onco-cardiology
Plain-language title
Checks heart and blood vessel side effects of cancer immunotherapy drugsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
14 January 2026